| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e75dbe74a46e1e3af10225913a7bfb4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e755886d8345fc60b12269c908f78a6f |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
2019-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74322fdc34f20acbba450e4dc5c3778f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f11ee2967e05e2bbc16d103c0391654 |
| publicationDate |
2021-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2021020873-A |
| titleOfInvention |
Lenalidomide derivatives and pharmaceutical compositions |
| abstract |
PROBLEM TO BE SOLVED: To provide a novel immunomodulatory agent capable of enhancing the interaction between CRBN and IKZF1. 6-Hydroxylenalidomide in which a hydroxyl group is bonded to the 6-position of the aminoisoindolinone ring of lenalidomide can enhance the interaction between CRBN and IKZF1 and can be used for the treatment of blood cancer. [Selection diagram] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023074780-A1 |
| priorityDate |
2019-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |